The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Feasibility and activity of two vinflunine (VFL)-based combinations as first-line chemotherapy (CT) in CDDP-unfit patients (pts) with advanced urothelial carcinoma (UC): VFL-gemcitabine (GEM) or VFL-CBDCA in a randomized international phase II trial (JASINT).
Maria De Santis
Consultant or Advisory Role - Celgene; Pierre Fabre Medicament (U); Shionogi
Honoraria - Pierre Fabre Medicament
Research Funding - Pierre Fabre Medicament
Pawel J. Wiechno
No relevant relationships to disclose
Christel Lucas
Employment or Leadership Position - Pierre Fabre Medicament
Research Funding - Pierre Fabre Medicament
Wu-Chou Su
No relevant relationships to disclose
Laurence Albiges
No relevant relationships to disclose
Chia-Chi Lin
Honoraria - Pierre Fabre Medicament
Joaquim Bellmunt
Consultant or Advisory Role - Pierre Fabre Medicament (U)
Elzbieta Senkus-Konefka
Honoraria - Pierre Fabre Medicament
Aude Flechon
Research Funding - Pierre Fabre Medicament
Loic Mourey
No relevant relationships to disclose
Andrea Necchi
No relevant relationships to disclose
Wolfgang C. Loidl
Consultant or Advisory Role - Pierre Fabre Medicament
Maryse Morand
Employment or Leadership Position - Pierre Fabre Medicament
Jean-Philippe Burillon
Employment or Leadership Position - Pierre Fabre Medicament
Ronan Fougeray
Employment or Leadership Position - Pierre Fabre Medicament
Stephane Culine
Consultant or Advisory Role - Pierre Fabre Medicament (U)
Honoraria - Pierre Fabre Medicament
Research Funding - Pierre Fabre Medicament